EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Fibroblast Growth Factor Receptor Inhibitors Decrease Proliferation of Melanoma Cell Lines and Their Activity Is Modulated by Vitamin D

Anna Piotrowska iD, Joanna I Nowak, Justyna M Wierzbicka iD, Paweł Domżalski, Monika Górska-Arcisz, Rafał Sądej, Delfina Popiel, Maciej Wieczorek, Michał A Żmijewski iD

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25052505 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Anna Piotrowska und 8 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Department of Histology, Medical University of Gdańsk, Dębinki 1a, 80-384 Gdańsk, Poland. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Centre for Research and Development, National Centre of Research and Development, pharmaceutical company Celon Pharma S.A..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Regardless of the unprecedented progress in malignant melanoma treatment strategies and clinical outcomes of patients during the last twelve years, this skin cancer remains the most lethal one. We have previously documented that vitamin D and its low-calcaemic analogues enhance the anticancer activity of drugs including a classic chemotherapeutic—dacarbazine—and an antiangiogenic VEGFRs inhibitor—cediranib. In this study, we explored the response of A375 and RPMI7951 melanoma lines to CPL304110 (CPL110), a novel selective inhibitor of fibroblast growth factor receptors (FGFRs), and compared its efficacy with that of AZD4547, the first-generation FGFRs selective inhibitor. We also tested whether 1,25(OH)2D3, the active form of vitamin D, modulates the response of the cells to these drugs. CPL304110 efficiently decreased the viability of melanoma cells in both A375 and RPMI7951 cell lines, with the IC50 value below 1 µM. However, the metastatic RPMI7951 melanoma cells were less sensitive to the tested drug than A375 cells, isolated from primary tumour site. Both tested FGFR inhibitors triggered G0/G1 cell cycle arrest in A375 melanoma cells and increased apoptotic/necrotic SubG1 fraction in RPMI7951 melanoma cells. 1,25(OH)2D3 modulated the efficacy of CPL304110, by decreasing the IC50 value by more than 4-fold in A375 cell line, but not in RPMI7951 cells. Further analysis revealed that both inhibitors impact vitamin D signalling to some extent, and this effect is cell line-specific. On the other hand, 1,25(OH)2D3, have an impact on the expression of FGFR receptors and phosphorylation (FGFR-Tyr653/654). Interestingly, 1,25(OH)2D3 and CPL304110 co-treatment resulted in activation of the ERK1/2 pathway in A375 cells. Our results strongly suggested possible crosstalk between vitamin D-activated pathways and activity of FGFR inhibitors, which should be considered in further clinical studies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

MelanomaSkin NeoplasmsHumansVitamin DReceptors, CalcitriolCell Line, TumorVitaminsReceptors, Fibroblast Growth FactorCell Proliferation

Stichwörter der Autor:innen

1,25(OH)2DAZD4547CPL304110FGFRFGFR inhibitorsmelanomavitamin D

Substanzen

Vitamin DReceptors, CalcitriolVitaminsReceptors, Fibroblast Growth Factor

Autor:innen und Institutionen

  • Faculty of Medicine, Department of Histology, Medical University of Gdańsk, Dębinki 1a, 80-384 Gdańsk, Poland.
  • Laboratory of Molecular Enzymology and Oncology, Intercollegiate Faculty of Biotechnology, University of Gdańsk and Medical University of Gdańsk, Dębinki 1, 80-384 Gdańsk, Poland.
  • Preclinical Development Departament, Celon Pharma S.A., Marymoncka 15, 05-152 Kazuń Nowy, Poland.
  • Clinical Development Department, Celon Pharma S.A., Marymoncka 15, 05-152 Kazuń Nowy, Poland.

ORCID-Profile: Anna Piotrowska, Justyna M Wierzbicka, Michał A Żmijewski

Förderung

  • National Centre for Research and Development
  • National Centre of Research and Development
  • pharmaceutical company Celon Pharma S.A.

Zitieren

APA

Piotrowska, A., Nowak, J. I., Wierzbicka, J. M., Domżalski, P., Górska-Arcisz, M., Sądej, R., Popiel, D., Wieczorek, M., & Żmijewski, M. A. (2024). Fibroblast Growth Factor Receptor Inhibitors Decrease Proliferation of Melanoma Cell Lines and Their Activity Is Modulated by Vitamin D. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25052505

Vancouver

Piotrowska A, Nowak JI, Wierzbicka JM, Domżalski P, Górska-Arcisz M, Sądej R, et al. Fibroblast Growth Factor Receptor Inhibitors Decrease Proliferation of Melanoma Cell Lines and Their Activity Is Modulated by Vitamin D. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25052505

BibTeX
@article{Piotrowska2024,
  author = {Piotrowska, Anna and Nowak, Joanna I and Wierzbicka, Justyna M and Domżalski, Paweł and Górska-Arcisz, Monika and Sądej, Rafał and Popiel, Delfina and Wieczorek, Maciej and Żmijewski, Michał A},
  title = {Fibroblast Growth Factor Receptor Inhibitors Decrease Proliferation of Melanoma Cell Lines and Their Activity Is Modulated by Vitamin D},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25052505}
}
Kostenlos starten →